Clinical

  1. Clinical

Geisinger enrolls first affected person in amyloid cardiomyopathy trial

DANVILLE, Pa., Could 10, 2024. Heart specialist Brendan Carry, MD, and a workforce of Geisinger physicians have enrolled the primary affected person within the U.S. right into a cardiac amyloidosis trial. The workforce can also be the primary to within the U.S. to display screen for the trial. “If a affected person qualifies for the […]
Written by
  1. Clinical

Constructive topline outcomes of Section 2 head and neck most cancers trial with lead NOX inhibitor candidate, setanaxib

STOCKHOLM, Could 6, 2024. Calliditas Therapeutics AB (“Calliditas”) at present introduced knowledge from the proof-of-concept Section 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, together with pembrolizumab, in sufferers with squamous cell carcinoma of the top and neck (SCCHN). The evaluation confirmed statistically important enhancements in progression-free survival (PFS), in addition to in total […]
Written by
  1. Clinical

Decrease Dose of Mpox Vaccine is Secure and Generates Six-Week Antibody Response Equal to Commonplace Routine

April 27, 2024 — A dose-sparing intradermal mpox vaccination routine was protected and generated an antibody response equal to that induced by the usual routine at six weeks (two weeks after the second dose), based on findings offered immediately on the European Society of Scientific Microbiology and Infectious Ailments World Congress in Barcelona. The outcomes […]
Written by
  1. Clinical

FDA Approves Scientific Trial for GFH925 Monotherapy in Section III Registrational Research Treating Metastatic Colorectal Most cancers

SHANGHAI, April 19, 2024. GenFleet Therapeutics, a clinical-stage biotechnology firm specializing in cutting-edge therapies in oncology and immunology, introduced US Meals and Drug Administration (FDA) has granted the medical trial approval for GFH925 (KRAS G12C inhibitor) in a multi-center, open-label, randomized and managed section III examine treating refractory metastatic colorectal most cancers (CRC) sufferers. It’s […]
Written by
  1. Clinical

TLX101-CDx (Pixclara) Granted FDA Quick Monitor Designation

Melbourne (Australia) | 16 April 2024 — Telix right this moment proclaims that america (U.S.) Meals and Drug Administration (FDA) has granted Quick Monitor designation1 for the Firm’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET). The granted Quick Monitor designation is for the characterisation of progressive or recurrent glioma utilizing positron emission […]
Written by
  1. Clinical

NRx Prescribed drugs Pronounces Information-Lock of Part 2b/3 Trial of NRX-101 in Suicidal Therapy Resistant Bipolar Despair

RADNOR, Pa., April 8, 2024. NRx Prescribed drugs, Inc. (“NRx Prescribed drugs”, the “Firm”), a clinical-stage biopharmaceutical firm, at this time introduced that the Firm has achieved data-lock in its Part 2b/3 Suicidal Therapy Resistant Bipolar Despair Research with NRX-101. With data-lock, as forecast in final week’s earnings name, the whole information set handed on […]
Written by
  1. Clinical

Amylyx Prescribed drugs Publicizes Interim Information From Ongoing Part 2 HELIOS Scientific Trial Demonstrating Enhancements in Pancreatic Operate and Glycemic Management with AMX0035 in Individuals with Wolfram Syndrome

CAMBRIDGE, Mass.–(BUSINESS WIRE) April 10, 2024 — Amylyx Prescribed drugs, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Firm”) immediately introduced interim information from the continued Part 2 HELIOS scientific trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults dwelling with Wolfram syndrome, a uncommon, progressive genetic illness impacting roughly 3,000 […]
Written by
  1. Clinical

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Sufferers with LVADs, RVADs, Biventricular Help Gadgets, and Whole Synthetic Hearts

PONTE VEDRA, Fla., April 9, 2024 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical firm growing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to forestall coronary heart assaults, strokes, and deaths as a consequence of blood clots in sufferers with uncommon cardiovascular circumstances, introduced immediately that the USA Meals and Drug […]
Written by
  1. Clinical

First-Affected person Dosed in Part 2 Scientific Examine Evaluating NBI-1070770 in Adults with Main Depressive Dysfunction

SAN DIEGO, April 3, 2024. Neurocrine Biosciences, Inc. right this moment introduced that the primary affected person has been randomized for its Part 2 scientific research to judge the efficacy, security, and tolerability of investigational compound NBI-1070770 in adults with main depressive dysfunction. NBI-1070770 is a novel, selective, and orally energetic, unfavorable allosteric modulator (NAM) […]
Written by
  1. Clinical

EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR

DOVER, Del., April 4, 2024. Eilean Therapeutics LLC, a biopharmaceutical firm devoted to discovering and growing best-in-class and first-in-class small molecule inhibitors to focus on escape mutations in hematologic and stable malignancies, is happy to announce the clearance from the Human Analysis Ethics Committee in Australia for lomonitinib (ZE46-0134) permitting the corporate to proceed with […]
Written by

Good Reads

New tentative approval for Alembic drug dabigatran etexilate mesylate

New patent for Vanda Pharms drug HETLIOZ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […]
Written by

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Worlwide

New tentative approval for Alembic drug dabigatran etexilate mesylate

New patent for Vanda Pharms drug HETLIOZ

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […]
Written by

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.